Related Experiment Video
Updated: Apr 30, 2026
08:55
Murine Model for Non-invasive Imaging to Detect and Monitor Ovarian Cancer Recurrence
Published on: November 2, 2014
12.7K
Surgery for Recurrent Ovarian Cancer.
1Florida Cancer Specialists and Research Institute, West Palm Beach, FL, USA.
Hematology/Oncology Clinics of North America
|October 31, 2025
Summary
Secondary cytoreductive surgery for recurrent ovarian cancer shows benefit, especially when complete gross resection is achieved. Patient and disease factors help predict surgical success in this controversial treatment approach.
Area of Science:
- Gynecologic Oncology
- Surgical Oncology
Background:
- The role of secondary cytoreductive surgery (SCS) in recurrent ovarian cancer (ROC) remains debated.
- Identifying patients who benefit from SCS is crucial for optimizing treatment strategies.
Purpose of the Study:
- To evaluate the efficacy of SCS in patients with recurrent ovarian cancer.
- To identify patient and disease factors predicting benefit from SCS.
Main Methods:
- Review of patient and disease factors associated with surgical benefit.
- Analysis of data from three parallel multicenter randomized controlled trials (RCTs) of SCS.
- Meta-analysis of RCTs to assess overall treatment effect.
Main Results:
- Complete gross resection of disease is the most significant factor for patient benefit.
- Selection criteria have been developed and validated to predict complete gross resection.
- Recent RCTs reported mixed results, but a meta-analysis indicates a survival benefit for SCS.
Conclusions:
- SCS can be beneficial in carefully selected recurrent ovarian cancer patients.
- Achieving complete gross resection is paramount for maximizing the benefits of SCS.
- Further research and refined selection criteria are needed to optimize SCS in recurrent ovarian cancer management.
